Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection

Status Terminated

Clinical Trial Summary

Liver resection have been a primary treatment option for lesions found in the liver. With improvements in surgical technique and perioperative patient management, morbidity and mortality related to liver resection have been greatly reduced. However, many patients with hepatocellular carcinoma have underlying liver disease. Severity of underlying liver disease plays an important role in decision making of resection extent. Therefore, liver failure and decreased liver function following liver resection still remains to be an critical issue.

Postresection liver failure is generally defined by serum total bilirubin greater than 3mg/dL and prothrombin time of less than 50% of normal (INR >1.7). Pathophysiology of postresection liver failure is not yet well known. However, sepsis after liver resection, small-for-size syndrome (SFSS), and ischemia/reperfusion injury are known to have important roles in persistant liver injury after resection.

After a liver resection, kupffer cells are drastically decreased and innate immunity of the patient is also damaged. This process causes the patient to be vulnerable to infection. In addition, with continuous endotoxin secretion, dysfunction in kupffer cells are triggered and liver regeneration is affected.

Complex mechanisms leading to dysfunctional kupffer cells and apoptosis and necrosis of hepatocytes are mediated by neutrophils, complement, reactive oxygen species, and acute inflammatory cytokines.

Recent studies have reported on many promising effects of the synthetic protease inhibitor, such as Gabexate mesilate. These include antioxidant effect, inhibition of acute inflammatory cytokine reaction, and anticoagulatory property. Based on these effects, synthetic protease inhibitor have gained attention in the role of hepatocyte protection after liver resection.

Currently, there is a report on the hepatocyte protective effects of Gabexate Mesilate on ischemia/reperfusion injury caused by the Pringle maneuver. However, with the advances in surgical technique and equipment, many surgeons now perform liver resection without Pringle maneuver. Therefore, this study was designed to determine effects of Gabexate Mesilate in the liver resection performed without Pringle maneuver.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02710266
Study type	Interventional
Source	Yonsei University
Contact
Status	Terminated
Phase	Phase 3
Start date	February 24, 2012
Completion date	February 25, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798861` - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed	`NCT01968395` - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure	Phase 4
Completed	`NCT01437969` - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting	`NCT00155376` - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography	Phase 4
Recruiting	`NCT00172705` - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique	N/A
Completed	`NCT04185454` - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese	N/A
Completed	`NCT02506335` - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease	Early Phase 1
Completed	`NCT02520609` - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed	`NCT02306018` - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation	N/A
Completed	`NCT01988753` - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed	`NCT01970904` - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients	N/A
Terminated	`NCT00741117` - Conjugated Hyperbilirubinemia and Pulse Oximetry	N/A
Enrolling by invitation	`NCT01483248` - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis	Phase 1/Phase 2
Completed	`NCT00245830` - Ischemic Preconditioning of Liver in Cadaver Donors	N/A
Completed	`NCT00074386` - Kidney and Liver Transplantation in People With HIV	N/A
Completed	`NCT02329821` - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection	N/A
Completed	`NCT01303549` - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients	Phase 4
Completed	`NCT01650181` - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis	Phase 4
Completed	`NCT00799851` - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices	Phase 4
Completed	`NCT00058890` - Gabapentin to Treat Itch in Patients With Liver Disease	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms